Literature DB >> 19821820

Immunotoxin BL22 induces apoptosis in mantle cell lymphoma (MCL) cells dependent on Bcl-2 expression.

Christian Bogner1, Tobias Dechow, Ingo Ringshausen, Michaela Wagner, Madlen Oelsner, Gloria Lutzny, Thomas Licht, Christian Peschel, Ira Pastan, Robert J Kreitman, Thomas Decker.   

Abstract

Mantle cell lymphoma (MCL) is an incurable mature B cell proliferation, combining the unfavourable clinical features of aggressive and indolent lymphomas. The blastic variant of MCL has an even worse prognosis and new treatment options are clearly needed. We analysed the effects of BL22, an immunotoxin composed of the Fv portion of an anti- CD22 antibody fused to a 38-kDa Pseudomonas exotoxin-A fragment on four MCL cell lines as well as on primary cells of four MCL patients. Apoptosis induction by BL22 was much more pronounced in MCL cell lines with low Bcl-2 expression (NCEB-1, JeKo-1 and JVM-2) compared to Granta-519 cells with high Bcl-2 expression. While the expression of the antiapoptotic protein Mcl-1 declined (NCEB-1, Granta-519), Bcl-2 levels remained unchanged in Granta-519 cells. However transfection of BCL2 cDNA into NCEB-1, JeKo-1 and JVM-2 cells significantly reduced BL22-mediated toxicity. Accordingly we examined the effects of Bcl-2 inactivation in Granta-519 cells using siRNA. Indeed, apoptosis induction was strongly enhanced in Granta-519 cells with silenced Bcl-2. Our results were confirmed in freshly isolated MCL-cells from patients with leukaemic MCL. We conclude that Bcl-2 expression is important for mediating resistance against the immunotoxin BL22 in MCL cells.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19821820      PMCID: PMC7435071          DOI: 10.1111/j.1365-2141.2009.07939.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  46 in total

Review 1.  Cell death: critical control points.

Authors:  Nika N Danial; Stanley J Korsmeyer
Journal:  Cell       Date:  2004-01-23       Impact factor: 41.582

Review 2.  The Bcl-2 protein family: sensors and checkpoints for life-or-death decisions.

Authors:  Christoph Borner
Journal:  Mol Immunol       Date:  2003-01       Impact factor: 4.407

3.  The BH3 mimetic ABT-737 targets selective Bcl-2 proteins and efficiently induces apoptosis via Bak/Bax if Mcl-1 is neutralized.

Authors:  Mark F van Delft; Andrew H Wei; Kylie D Mason; Cassandra J Vandenberg; Lin Chen; Peter E Czabotar; Simon N Willis; Clare L Scott; Catherine L Day; Suzanne Cory; Jerry M Adams; Andrew W Roberts; David C S Huang
Journal:  Cancer Cell       Date:  2006-11       Impact factor: 31.743

Review 4.  The Bcl-2 apoptotic switch in cancer development and therapy.

Authors:  J M Adams; S Cory
Journal:  Oncogene       Date:  2007-02-26       Impact factor: 9.867

Review 5.  Regulation of mitochondrial morphological dynamics during apoptosis by Bcl-2 family proteins: a key in Bak?

Authors:  Craig Brooks; Zheng Dong
Journal:  Cell Cycle       Date:  2007-10-02       Impact factor: 4.534

6.  Efficacy of the anti-CD22 recombinant immunotoxin BL22 in chemotherapy-resistant hairy-cell leukemia.

Authors:  R J Kreitman; W H Wilson; K Bergeron; M Raggio; M Stetler-Stevenson; D J FitzGerald; I Pastan
Journal:  N Engl J Med       Date:  2001-07-26       Impact factor: 91.245

7.  High-dose chemoradiotherapy and anti-B-cell monoclonal antibody-purged autologous bone marrow transplantation in mantle-cell lymphoma: no evidence for long-term remission.

Authors:  A S Freedman; D Neuberg; J G Gribben; P Mauch; R J Soiffer; D C Fisher; K C Anderson; N Andersen; R Schlossman; M Kroon; J Ritz; J Aster; L M Nadler
Journal:  J Clin Oncol       Date:  1998-01       Impact factor: 44.544

8.  Apoptosis induced by immunotoxins used in the treatment of hematologic malignancies.

Authors:  A Keppler-Hafkemeyer; R J Kreitman; I Pastan
Journal:  Int J Cancer       Date:  2000-07-01       Impact factor: 7.396

9.  Quantitative analysis of bcl-2 expression in normal and leukemic human B-cell differentiation.

Authors:  P Menendez; A Vargas; C Bueno; S Barrena; J Almeida; M De Santiago; A López; S Roa; J F San Miguel; A Orfao
Journal:  Leukemia       Date:  2004-03       Impact factor: 11.528

Review 10.  Mantle-cell lymphoma.

Authors:  E Campo; M Raffeld; E S Jaffe
Journal:  Semin Hematol       Date:  1999-04       Impact factor: 3.851

View more
  15 in total

1.  The cytotoxicity of anti-CD22 immunotoxin is enhanced by bryostatin 1 in B-cell lymphomas through CD22 upregulation and PKC-βII depletion.

Authors:  Viola Biberacher; Thomas Decker; Madlen Oelsner; Michaela Wagner; Christian Bogner; Burkhard Schmidt; Robert J Kreitman; Christian Peschel; Ira Pastan; Christian Meyer Zum Büschenfelde; Ingo Ringshausen
Journal:  Haematologica       Date:  2011-12-16       Impact factor: 9.941

2.  CD22 is a recycling receptor that can shuttle cargo between the cell surface and endosomal compartments of B cells.

Authors:  Mary K O'Reilly; Hua Tian; James C Paulson
Journal:  J Immunol       Date:  2010-12-22       Impact factor: 5.422

Review 3.  The development of immunoconjugates for targeted cancer therapy.

Authors:  Brandon G Smaglo; Dalal Aldeghaither; Louis M Weiner
Journal:  Nat Rev Clin Oncol       Date:  2014-09-30       Impact factor: 66.675

4.  Combination treatments with ABT-263 and an immunotoxin produce synergistic killing of ABT-263-resistant small cell lung cancer cell lines.

Authors:  Abid R Mattoo; David J FitzGerald
Journal:  Int J Cancer       Date:  2012-08-16       Impact factor: 7.396

5.  Production of unique immunotoxin cancer therapeutics in algal chloroplasts.

Authors:  Miller Tran; Christina Van; Daniel J Barrera; Pär L Pettersson; Carlos D Peinado; Jack Bui; Stephen P Mayfield
Journal:  Proc Natl Acad Sci U S A       Date:  2012-12-10       Impact factor: 11.205

6.  ABT-737 overcomes resistance to immunotoxin-mediated apoptosis and enhances the delivery of pseudomonas exotoxin-based proteins to the cell cytosol.

Authors:  Roberta Traini; Gal Ben-Josef; Diana V Pastrana; Elizabeth Moskatel; Ashima K Sharma; Antonella Antignani; David J Fitzgerald
Journal:  Mol Cancer Ther       Date:  2010-06-29       Impact factor: 6.261

7.  Anti-CD22 antibody targeting of pH-responsive micelles enhances small interfering RNA delivery and gene silencing in lymphoma cells.

Authors:  Maria C Palanca-Wessels; Anthony J Convertine; Richelle Cutler-Strom; Garrett C Booth; Fan Lee; Geoffrey Y Berguig; Patrick S Stayton; Oliver W Press
Journal:  Mol Ther       Date:  2011-05-31       Impact factor: 11.454

Review 8.  Mechanisms of action of therapeutic antibodies for cancer.

Authors:  J M Redman; E M Hill; D AlDeghaither; L M Weiner
Journal:  Mol Immunol       Date:  2015-04-23       Impact factor: 4.407

Review 9.  Antibody-based therapeutics for the treatment of human B cell malignancies.

Authors:  Sivasubramanian Baskar; Natarajan Muthusamy
Journal:  Curr Allergy Asthma Rep       Date:  2013-02       Impact factor: 4.806

10.  Lipidoid nanoparticle mediated silencing of Mcl-1 induces apoptosis in mantle cell lymphoma.

Authors:  Christopher M Knapp; Jia He; John Lister; Kathryn A Whitehead
Journal:  Exp Biol Med (Maywood)       Date:  2016-03-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.